Overview

Between 2020 and 2026, health authorities in at least seven countries commissioned independent reviews of the evidence behind puberty blockers, cross-sex hormones and surgery for gender-distressed young people. These were not activist reports or opinion pieces: most were systematic reviews — structured searches of all published studies, with each study graded for quality using pre-set rules. They were carried out by evidence-review teams in England, Finland, Sweden, Norway, the United States and elsewhere, and they reached strikingly similar conclusions.

The common finding is that the evidence that these treatments improve the mental health of young people is of low or very low certainty (grades on a formal evidence scale, explained below), while long-term risks to bone, fertility, sexual function and brain development are poorly studied. Several countries moved from treating medical transition as routine care to treating it as an exception or a research-only intervention, and put psychological support first.

What "very low certainty" means

Most of the reviews grade evidence with GRADE (Grading of Recommendations, Assessment, Development and Evaluation), the standard system used by bodies such as England's National Institute for Health and Care Excellence (NICE) and the World Health Organization. GRADE asks one question about each outcome: how confident can we be that the true effect is close to what the studies report?

• High certainty: further research is very unlikely to change the conclusion.
• Moderate certainty: the true effect is probably close to the estimate, but could be substantially different.
• Low certainty: the true effect may be substantially different from the estimate.
• Very low certainty: we have very little confidence in the estimate; the true effect is likely to be substantially different.

Evidence starts lower when studies are observational (no randomisation), and drops further for small samples, no comparison group, short follow-up, many participants lost to follow-up, or confounding (for example, young people receiving hormones also receiving therapy and family support at the same time). Most studies in youth gender medicine have several of these problems at once.

In plain language, "very low certainty" does not mean "proven harmful" or "proven useless". It means we do not know. A 2025 systematic review by Miroshnychenko and colleagues, whose authors include GRADE co-founder Gordon Guyatt, put it this way about puberty blockers ("GD" is gender dysphoria):

The best available evidence reporting the effects of puberty blockers in individuals with GD was mostly very low certainty and therefore we cannot exclude the possibility of benefit or harm. — (Miroshnychenko et al. 2025)

Its companion review of cross-sex hormones in people under 26 reached the same conclusion for gender dysphoria, depression, global functioning and suicide, finding high-certainty evidence for only one outcome: about 4% of females on testosterone had a cardiovascular event over 7–109 months of follow-up (Miroshnychenko et al. 2025). The gap matters ethically. A treatment that is permanent, affects fertility and is given to children normally needs strong evidence of benefit; here the clearest evidence concerns harm.

The affirmation model and WPATH SOC8

What "gender-affirming care" means

Gender-affirming care is the umbrella term for social, hormonal and surgical interventions that help a person live as the opposite sex or as a "non-binary" identity. The affirmation model treats a young person's stated gender identity as something to be accepted and supported rather than explored, and treats medical transition as the main remedy for distress. It grew out of the Dutch protocol (puberty blockers from about 12, hormones from 16 and surgery from 18), developed in the 1990s for a small, carefully screened group of children with distress since early childhood.

From around 2012 the population changed sharply: referrals rose many times over, the majority became adolescent females, and many had no childhood history of dysphoria but did have depression, anxiety, autism or trauma (see demographic shift in trans identification). The evidence from the Dutch cohort was not clearly applicable to this new group, but practice expanded anyway. Critics such as Jorgensen argue that the affirmation model's thin assessment and minimisation of risk have produced iatrogenic harm — harm caused by treatment itself — visible in a growing number of young detransitioners (Jorgensen 2023).

WPATH Standards of Care 8

The World Professional Association for Transgender Health (WPATH) published its eighth Standards of Care (SOC8) in September 2022. Unlike its predecessor (SOC7), it set no minimum ages for hormones or most surgeries. Documents later unsealed in Boe v. Marshall, the US lawsuit over Alabama's ban on youth gender medicine, showed that a draft had proposed minimums (14 for hormones, 15 for mastectomy, 16–17 for most other surgeries, 18 for phalloplasty), and that these were removed after pressure from then-US Assistant Secretary for Health Rachel Levine, who was concerned that age limits would fuel restrictive legislation (Texas Attorney General amicus brief summarising the court record). WPATH's chair Eli Coleman later disputed this characterisation in a court filing. WPATH itself says the ages were replaced by "strengthened criteria" because one-size-fits-all models are not appropriate.

The same records showed WPATH had commissioned systematic reviews from a Johns Hopkins University evidence team, and that the team reported finding "little to no evidence about children and adolescents" and that WPATH was trying to restrict its ability to publish (Sex Matters; Society for Evidence-Based Gender Medicine (SEGM)). Only two of the reviews were published. SOC8's adolescent chapter states that a systematic review of adolescent outcomes "is not possible" — a claim GRADE co-founder Gordon Guyatt rejected in the BMJ, saying "systematic reviews are always possible" even when few studies qualify (Block 2023). Separately, the March 2024 "WPATH Files" leak of internal discussions showed members acknowledging that some adolescents could not understand the fertility and sexual consequences they were consenting to (commentary in the South African Journal of Psychiatry). That problem is the subject of the informed consent critique.

For what happened inside WPATH while SOC8 was written (the leaked internal discussions, the evidence reviews it commissioned from Johns Hopkins and then restricted, and the removal of age minimums), see WPATH: the Files, suppressed reviews and scandals.

United Kingdom: NICE and the Cass Review

NICE evidence reviews (2020)

NHS England commissioned NICE to review the evidence on puberty blockers and cross-sex hormones in under-18s. Both reviews, dated October 2020, rated every outcome as very low certainty. For puberty blockers, results on gender dysphoria, depression, anxiety, body image and psychosocial functioning "suggest little change" from baseline to follow-up. For hormones, all included studies were uncontrolled and observational, and NICE concluded that any benefits "must be weighed against the largely unknown long-term safety profile" (NICE reviews summarised by the Clinical Advisory Network on Sex and Gender).

The Cass Review (2024)

Paediatrician Hilary Cass was appointed in 2020 to review NHS gender identity services for children. Her final report, published on 10 April 2024, was supported by a programme of research from the University of York, including systematic reviews of puberty blockers, hormones, social transition, psychosocial interventions, patient characteristics and clinical guidelines (Cass 2024). Its main findings:

• Weak evidence: the field had been "operating on a remarkably weak evidence base", particularly for puberty blockers and hormones (Cass 2024). The York review of puberty suppression found 50 studies, of which one was high quality and 24 low quality; it concluded that "no conclusions can be drawn" about effects on gender dysphoria, mental health or cognitive development, and that bone health and height "may be compromised" (Taylor et al. 2024).
• Poor-quality guidelines: York appraised 23 international guidelines using the AGREE II tool, a standard checklist for rating the quality of clinical guidelines. Most lacked independence and rigour, WPATH's included; only the Swedish and Finnish guidelines could be recommended. Many guidelines described weak evidence and then cited each other to recommend treatment anyway — a circularity Cass suggested "may explain why there has been an apparent consensus on key areas of practice despite the evidence being poor" (Christian Medical & Dental Associations summary; BMJ).
• Complex patients: many young people had co-occurring mental health conditions or neurodevelopmental differences that were being overshadowed by the focus on gender (see mental health). Identity in adolescence "may evolve over time".
• Social transition is an intervention: Cass described social transition as "an active intervention" that is "not a neutral act", because it may affect psychological functioning and the path a young person takes.

Cass recommended that puberty blockers be offered only within a research protocol, that hormones from 16 be approached with "extreme caution", and that care move to regional services providing holistic assessment and evidence-based psychological treatment — an approach close to gender exploratory therapy.

What happened next

NHS England stopped routine prescription of puberty blockers in March 2024. An emergency order in June 2024 banned private and overseas prescriptions, and in December 2024 the government made the ban indefinite from 1 January 2025 after the Commission on Human Medicines advised there was "an unacceptable safety risk" outside research, with a review due in 2027 (Pharmaceutical Journal). A £10.7 million trial, PATHWAYS, run by King's College London, was announced in November 2025 to study around 220 children (BBC). It was later paused after the medicines regulator asked for a higher minimum age of 14, closer bone-density monitoring and a more rigorous consent process (BBC). Some clinicians and detransitioners oppose the trial outright, arguing that giving a drug with known risks to children in order to study it is itself unethical. More on the drugs themselves is on the puberty blockers page.

The UK review followed years of internal warnings about the national children's clinic, the Tavistock's Gender Identity Development Service (GIDS). See the Tavistock GIDS: rise, whistleblowers and closure.

The Nordic countries

Finland (COHERE, 2020)

Finland's Council for Choices in Health Care (COHERE/PALKO) issued recommendations in 2020 after its own literature review. It concluded that "the first-line treatment for gender dysphoria is psychosocial support and, as necessary, psychotherapy and treatment of possible comorbid psychiatric disorders". Puberty suppression may be considered only in clear cases of childhood-onset dysphoria that intensified at puberty; hormones may start no earlier than 16, and only where there is no co-occurring psychiatric illness requiring treatment. No surgeries are performed on minors (COHERE recommendation, unofficial translation). The document also noted that cross-sex identification in childhood "generally disappears during puberty".

Sweden (Socialstyrelsen, 2022)

Sweden's Karolinska University Hospital stopped using puberty blockers for minors outside research in May 2021. In 2022 the National Board of Health and Welfare (Socialstyrelsen) updated the national guideline for children and adolescents with gender dysphoria. Its conclusion was the bluntest of any national body:

At group level … the National Board of Health and Welfare currently assesses that the risks of puberty blockers and gender-affirming treatment are likely to outweigh the expected benefits of these treatments. — (Socialstyrelsen 2022, via SEGM)

Puberty blockers, hormones and mastectomy may be given only "in exceptional cases", ideally within research.

Norway (UKOM, 2023)

In March 2023 the Norwegian Healthcare Investigation Board (UKOM) found that "research-based knowledge for gender-affirming treatment (hormonal and surgical), is insufficient and the long-term effects are little known", especially for adolescents, "where the stability of their gender incongruence is also not known". It noted that the long-term studies that exist began before the recent increase in teenage patients, many of whom have mental illness or developmental disorders, so their conclusions are "not necessarily transferable". UKOM recommended that puberty blockers, hormones and surgery for young people be defined as experimental treatment and that the national guideline be rewritten on a systematic evidence base (Washington Stand summary of the UKOM report). A large cohort study from Norway's national clinic, covering 1,258 young people over two decades, found that 97% of those who started puberty blockers went on to hormones and that detransition was probably under-counted because people who stop treatment tend to disengage from the clinic (Nyquist et al. 2025, retracted 2026).

Denmark (2023)

Denmark did not publish a formal systematic review but changed practice quietly. Referrals to its centralised clinic rose from 4 in 2014 to 352 in 2022. The share of referred young people given blockers or hormones peaked at 65% in 2018 and fell to 6% in 2022. In 2023 the health minister told parliament that medical treatment would mainly be offered to those with dysphoria since childhood, and the Danish Medical Association's journal described "a more cautious approach to hormone therapy until more evidence is available for its beneficial effect" (SEGM; Gender Clinic News).

United States: the HHS review (2025)

The US Department of Health and Human Services released Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices on 1 May 2025, following a presidential executive order. A peer-reviewed final version with a 241-page supplement of nine external peer reviews and replies, including a critique from the American Psychiatric Association, followed on 19 November 2025 (SEGM). Its umbrella review concluded that the quality of evidence for effects of puberty blockers, hormones and surgery on psychological outcomes, quality of life and long-term health in minors "is very low" (HHS summary). It argued that the risk–benefit balance is unfavourable and recommended psychotherapy as the primary approach.

The HHS review is the most politically contested of all the reviews. Its authors were initially anonymous, it was ordered by an administration openly hostile to youth transition, and critics including medical associations accused it of endorsing "exploratory therapy" as a form of conversion therapy (KFF). Its core evidence finding, however, matches the European reviews and the independent Miroshnychenko reviews. In February 2026 the American Society of Plastic Surgeons (ASPS) became the first major US medical society to break from the affirmation consensus, recommending that chest, genital and facial surgery be delayed until at least 19 because of "insufficient evidence demonstrating a favorable risk-benefit ratio" (HealthExec; AP). Other major US medical groups have stood by their existing guidance (NBC News).

Other countries

• France: in February 2022 the National Academy of Medicine urged "great medical caution" in children and adolescents, given their psychological vulnerability and the "many undesirable effects" of treatment, and prioritised psychological support (Académie nationale de médecine).
• New Zealand: a November 2024 Ministry of Health evidence brief found significant limitations in the evidence on puberty blockers. The government banned new prescriptions for gender dysphoria from 19 December 2025, but the High Court ordered that the ban not be enforced pending a full judicial review, and released papers showed officials had advised keeping the status quo (NZ Ministry of Health; Newsroom).
• Australia (Queensland): Queensland paused puberty blockers and hormones for new adolescent patients in its public system in 2025, and extended the pause in December 2025 after a 530-page independent review by Professor Ruth Vine found the evidence base "extremely limited" (ABC).
• Brazil: in April 2025 the Federal Council of Medicine banned puberty blockers for all minors, hormones before 18 and some surgeries before 21 (medRxiv).

Country comparison

Critiques of the Cass Review

The Yale Integrity Project paper

In July 2024 a group led by Yale paediatrician Meredithe McNamara and law professor Anne Alstott published An Evidence-Based Critique of "The Cass Review" (McNamara et al. 2024). Its main arguments were:

• The Review "does not recommend a ban" on medical care, and parts of it are consistent with WPATH and Endocrine Society models.
• The York reviews departed from their registered protocols and used an adapted quality scale that excluded low-quality studies from synthesis, so that most of the evidence was set aside.
• More broadly, defenders of the affirmation model argue that randomised trials are neither feasible nor ethical here, so demanding high-certainty evidence sets an impossible bar.
• Restricting treatment to research settings is "coercive and unethical", and the Review repeats "debunked" claims, for example about social contagion.

The BMC Medical Research Methodology paper

A peer-reviewed critique by Noone and colleagues, published in 2025, applied the ROBIS risk-of-bias tool to the seven York reviews and rated all of them at high risk of bias, citing "unexplained protocol deviations, ambiguous eligibility criteria, inadequate study identification", and failure to carry these limitations into the conclusions (Noone et al. 2025).

Responses

A detailed reply by McDeavitt, Cohn and Levine fact-checked the published critiques claim by claim (McDeavitt et al. 2025). Among their points: the Review never claimed detransition was rare — its emphasis was on the absence of follow-up data — and it did describe the intended benefits of blockers and hormones. SEGM noted that the York team did not give WPATH or Endocrine Society guidelines a positive appraisal, contrary to how the Yale paper presented them, and that protocol changes of the kind York made are common practice (SEGM). A widely repeated claim that Cass "threw out 98% of studies" is also wrong: the York puberty-blocker review excluded 24 low-quality studies from synthesis out of 50, and used the remaining 26 (Taylor et al. 2024). The Yale paper was also written explicitly to inform US litigation over youth treatment (Yale Law School), which critics argue undermines its claim to neutrality.

Assessment

Some of the criticism is fair. The York reviews were not flawless, a narrative synthesis involves judgement, and Cass did not call for a total ban — that was a political decision taken afterwards. The real weakness of the critiques, though, is that none of them produces the missing evidence. Every independent review that has looked — NICE, Sweden, Finland, Norway, York, McMaster University (the Miroshnychenko reviews) and HHS, using different teams and methods — reached the same basic conclusion. If York's methods were biased, the Miroshnychenko reviews, which used standard GRADE meta-analysis rather than York's adapted scale, should have found something different. They did not (Miroshnychenko et al. 2025).

The argument that randomised trials are impossible explains why the evidence is weak; it does not make it strong. Low-certainty evidence is sometimes enough in medicine when a condition is life-threatening, the treatment is reversible, or there is no alternative. Youth gender dysphoria often resolves without medical treatment, the interventions are partly or fully irreversible, and psychological support is an alternative. Under those conditions, as the bioethicist Moti Gorin argues, adolescents' wish for particular sex characteristics cannot by itself justify interventions whose health benefits have not been shown (Gorin 2024). Defenders of the affirmation model have increasingly shifted their argument from health outcomes to autonomy and "embodiment goals" — which is itself an admission that the outcome evidence is weak. The claim that transition prevents suicide is examined separately in suicide and transition.

How the reviews treat detransition

Almost every review says the same thing about detransition: nobody knows how common it is. This is not a neutral gap. The figures of under 1% often quoted as the "regret rate" come mostly from older adult cohorts, short follow-up and studies that lost track of many patients. Observed times to detransition or regret are often several years, so short studies systematically miss it (Cohn 2023). A 2024 systematic review of detransition among people who started blockers or hormones concluded that detransition "has been insufficiently investigated" and called for proper long-term monitoring (Feigerlova 2025).

Where data exists, it suggests the question matters. In US military health records, about 30% of people who started hormones had stopped within four years, more often among females (Roberts et al. 2022). A UK adult clinic audit concluded that "detransitioning might be more frequent than previously reported" (Hall et al. 2021). Stopping hormones is not always the same as detransition, but it shows how little is known.

The Cass Review tried to fill this gap with a data linkage study that would have followed around 9,000 young people from the children's service into adult clinics. All but one of the adult gender clinics refused to cooperate, so the Review was published without outcome data (SEGM; McDeavitt et al. 2025). The clinics later relented under pressure (The Guardian), and Cass made completing the study a formal recommendation, but at the time of writing its results have not been published (Sex Matters).

Detransitioners on /r/detrans often explain the missing data from personal experience. A recurring theme is that people simply stop attending, and clinics do not follow up:

I never talked to the doctor at the gender clinic ever again after I stopped hormones so how would they even know I detransitioned? —Lurkersquid, detrans female

Others describe trying to be counted and being refused:

They told me they would leave my file open for 2 years in case I want to retransition. I said no, told them to close my file, and to write down the reason as "detransition" so that it could be officially recorded in statistics. They refused. —wildflowerden, detrans female

These accounts cannot be used to estimate a rate, but they explain why clinic-based figures will tend to undercount.

Detransitioner reactions

Many detransitioners on /r/detrans describe the Cass Review as long-awaited confirmation of what they had experienced. Some recognised themselves in its data on the rise in adolescent referrals:

…that huge boom after around 2011/2012 … is exactly what I expected since that is the exact time I was becoming trans and this shows me more that I really was in that first "wave" of when transitioning became "popular" .. it's crazy. —DEVlLlSH, detrans female

Others focus on what the Review says about affirmation as a default:

The Cass Review was a comprehensive study including meta-analysis of existing studies that showed inconclusive evidence that intervening in cases of child gender dysphoria was helpful. That is to say, the standards of care, particularly affirming as the default position, offered no measured benefit. —__per_capita__, detrans male

The language of experimentation comes up repeatedly. For people who were given treatments that national reviews now describe as experimental, the word is not hyperbole but a description of being treated without the evidence base they were told existed:

A treatment is when you already know what the outcomes are. More short and long term effects of transition are being discovered all the time and/or ignored by the medical industry (up until events like the Cass report and the Tavistock investigation), therefore making it an experiment. —shadowthehedgehoe, detrans

A common view among commenters is that better assessment helps everyone, including those who go on to transition:

We're really letting them down with affirmative care. More therapy and time to get to know the patient and their medical history is crucial, and it's insane that this is controversial. —PeregrinePanic, detrans female

Trans reactions

Trans commenters on r/ftm and r/MtF see the reviews very differently. Many describe the Cass Review as discredited and point to the Yale paper and the BMC critique:

The Cass Report was already debunked as nonsense by Yale … There are extensive studies that show only positive benefits for trans people on HRT… —son-of-may, trans man (FTM)

Others see the reviews as political, reading the HHS review in particular as concluding "transition doesn't work, at all" (Reagalan, trans woman (MTF)). Their fear is real: many adults who are content with their transition worry that restrictions on minors will spread to adults, and that losing access will harm young people. Some cite their own experience of wishing they had been given blockers earlier.

These concerns deserve to be taken seriously, but they rest on a misreading of what the reviews say. The reviews do not claim that every trans-identified adult regrets transition, and the critiques do not show that the evidence for youth treatment is strong. They mostly argue that the reviews set the bar too high. Statements that "extensive studies show only positive benefits" are not supported by any systematic review. The disagreement is less about the data than about how much uncertainty is acceptable when the patients are children and the effects are permanent.

What this means

The reviews have changed the debate. The claim that youth medical transition is "settled science" is no longer tenable: the strongest available reviews, from multiple countries and methods, find the evidence of benefit to be low or very low certainty. Several countries have responded by putting psychological care first, limiting medical treatment to exceptional cases or research, and recognising that adolescent identity can change.

Two things remain unresolved: the long-term outcomes of young people already treated, including how many detransition, are still largely unmeasured; and research trials of puberty blockers raise their own ethical problem of giving drugs with known risks to children in order to find out whether they help.

For detransitioners, the reviews offer recognition that the treatments they received were never as well supported as they were told. For anyone affected now, the practical consequence is the same: informed consent must include the honest message that the benefits are uncertain and the risks are real. Peer-reviewed studies on these questions are collected in the study archive, and support resources list gender-exploratory therapists and detransition support groups.

Related pages

• Puberty blockers
• Suicide and transition
• Informed consent in gender medicine
• Iatrogenic harm
• Social transition
• Gender exploratory therapy
• Autism and gender identity
• Mental health and gender distress
• Detransition overview

References

• Cass, H. (2024). Independent review of gender identity services for children and young people: Final report. study page, source.
• Taylor, J. et al. (2024). Interventions to suppress puberty in adolescents experiencing gender dysphoria or incongruence: a systematic review. Archives of Disease in Childhood. source.
• Miroshnychenko, A. et al. (2025). Puberty blockers for gender dysphoria in youth: A systematic review and meta-analysis. Archives of Disease in Childhood. study page, source.
• Miroshnychenko, A. et al. (2025). Gender affirming hormone therapy for individuals with gender dysphoria aged <26 years: a systematic review and meta-analysis. Archives of Disease in Childhood. study page, source.
• Block, J. (2023). Gender dysphoria in young people is rising—and so is professional disagreement. The BMJ. study page, source.
• Jorgensen, S. C. J. (2023). Iatrogenic Harm in Gender Medicine. Journal of Sex & Marital Therapy. study page, source.
• Gorin, M. (2024). The Aims of Medicine in Pediatric Gender Care: Against the Autonomy-Based View. Hastings Center Report. study page, source.
• Cohn, J. (2023). The Detransition Rate Is Unknown. Archives of Sexual Behavior. study page, source.
• Feigerlova, E. (2025). Prevalence of detransition in persons seeking gender-affirming hormonal treatments: a systematic review. Journal of Sexual Medicine. study page, source.
• Roberts, C. M. et al. (2022). Continuation of Gender-affirming Hormones Among Transgender Adolescents and Adults. Journal of Clinical Endocrinology & Metabolism. study page, source.
• Hall, R., Mitchell, L., Sachdeva, J. (2021). Access to care and frequency of detransition among a cohort discharged by a UK national adult gender identity clinic. BJPsych Open. study page, source.
• Nyquist, C. B. et al. (2025). Treatment trajectories among children and adolescents referred to the Norwegian National Center for Gender Incongruence. study page, source.
• National Institute for Health and Care Excellence (2020). Evidence reviews: GnRH analogues and gender-affirming hormones for children and adolescents with gender dysphoria. summary.
• Council for Choices in Health Care in Finland (COHERE) (2020). Medical Treatment Methods for Dysphoria Related to Gender Variance in Minors. unofficial translation.
• Socialstyrelsen (2022). Care of children and adolescents with gender dysphoria. SEGM summary and translation.
• Norwegian Healthcare Investigation Board (UKOM) (2023). Patient safety for children and adolescents with gender incongruence. summary.
• SEGM (2023). Denmark Joins the List of Countries That Have Sharply Restricted Youth Gender Transitions. source; Gender Clinic News (2023). Doubt in Denmark. source.
• French National Academy of Medicine (2022). Medicine and gender transidentity in children and adolescents. source.
• US Department of Health and Human Services (2025). Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices. HHS summary, SEGM release note, KFF critique summary.
• American Society of Plastic Surgeons position statement (2026). HealthExec, AP, NBC News.
• New Zealand Ministry of Health (2025). Puberty blockers. source; Newsroom (2025). Cabinet overrode health advice in decision to ban puberty blockers. source.
• ABC News (2025). Queensland government to continue pause on puberty blockers. source.
• Brazil Federal Council of Medicine Resolution 2.427/2025, described in A Rapid Assessment of Stakeholder Agreement with Brazil's New Gender-Affirming Care Restrictions (2025). medRxiv.
• Pharmaceutical Journal (2024). Ban on puberty blockers in the UK made indefinite. source; BBC (2025). New puberty blockers trial to begin after UK ban. source; BBC (2026). Puberty blockers trial paused over concerns from medicines watchdog. source.
• BMJ (2024). Guidelines on gender related treatment flouted standards and overlooked poor evidence, finds Cass review. source; CMDA (2024). The Cass Review Final Report (UK). source.
• McNamara, M., Alstott, A. et al. (2024). An Evidence-Based Critique of "The Cass Review" on Gender-affirming Care for Adolescent Gender Dysphoria. The Integrity Project, Yale. source, Yale Law School press release.
• The Guardian (2024). The Cass review of gender identity services marks a return to reason and evidence. source; Sex Matters (2025). Baroness Cass is wrong about the puberty-blocker trial. source.
• Noone, C. et al. (2025). Critically appraising the Cass report: methodological flaws and unsupported claims. BMC Medical Research Methodology 25:128. source.
• McDeavitt, K., Cohn, J., Levine, S. B. (2025). Critiques of the Cass Review: Fact-Checking the Peer-Reviewed and Grey Literature. Journal of Sex & Marital Therapy 51(2):175–199. source.
• SEGM (2024). The Cass Review, the "Yale" Report, and the Importance of Keeping Special Interests at Bay. source; SEGM (2024). The Final Cass Review and the NHS England Response. source.
• Sex Matters (2024). WPATH evidence on trial. source; SEGM (2024). WPATH Influence Undermines WHO's Transgender Guidelines. source; Texas Attorney General amicus brief, Nos. 24-2838 & 24-3240. source.
• A call for SASOP to review their position on the care of 'transgender and non-binary youth' (2025). source.